Special Issue: GLP-1 agonists in Parkinson’s disease: New evidence, new questions?

In this engaging discussion, Professor Tom Foltynie from University College London delves into a recent phase 3 clinical trial of exenatide for Parkinson’s disease. Despite disappointment in the results, he examines potential reasons behind the discrepancies from earlier studies. Foltynie explores how GLP-1 agonists could still play a vital role in early-stage Parkinson’s treatment and details advancements in clinical trial designs, which may pave the way for more effective therapies. Tune in for insights into the future of Parkinson’s research!